Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Spotlight picks
- New trial Spotlight
Multiple solid tumors
Phase 1 ML261 DLL3-targeted CAR-T with CARD11–PIK3R3 “armoring” fusion in R/R SCLC/NECs.
This first-in-human, open-label Phase 1 trial (SPECTRAL-1) evaluates ML261, an autologous anti-DLL3 chimeric antigen receptor (CAR) T-cell therapy that also expresses a CARD11–PIK3R3 fusion transgene intended to…
NCT07488923 First-in-human - Trial result Spotlight
Non-small cell lung cancer
Taletrectinib (CNS-penetrant ROS1 TKI) posts ~90% ORR and ~46-mo mPFS in ROS1+ NSCLC first-line
Taletrectinib is an oral, next-generation, selective ROS1 tyrosine kinase inhibitor (TKI) with CNS activity; this pooled update of the single-arm Phase 2 TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials…
NCT04395677 - Trial result Spotlight
Multiple myeloma
Cilta-cel (BCMA CAR-T) drives 100% MRD(10⁻⁶) negativity by 2 months in high-risk SMM
Ciltacabtagene autoleucel (cilta-cel) is a BCMA-targeted autologous CAR-T; in the CAR-PRISM Phase 2 trial (NCT05767359), HR-SMM patients received a single cilta-cel infusion (0.3–0.5×10⁶ or >0.5×10⁶ viable CAR+ T…
NCT05767359 - Trial result Spotlight
Prostate cancer
Niraparib (PARP inhibitor) + abiraterone (CYP17 inhibitor) drives 38.6-mo rPFS in BRCA2+ Asian 1L mCRPC
Niraparib is an oral PARP inhibitor that exploits homologous recombination repair deficiency; here it was combined with abiraterone acetate + prednisone (AAP), an androgen biosynthesis (CYP17) inhibitor backbone, in…
NCT03748641 - New trial Spotlight
Brain and CNS tumors
Phase 1 EGFR/IL13Rα2 pool-CAR T cells target EGFR + IL13Rα2 in HGG
City of Hope Medical Center is running a Phase 1, first-in-human, open-label, dose-finding study of autologous “pool-CAR” T cells engineered to recognize EGFR and IL13Rα2 on tumor cells (dual-antigen CAR T…
NCT07544992 First-in-human - New trial Spotlight
Prostate cancer
Phase 1 JANX014 PSMA-directed CD3 T cell engager (tumor-activated, double-masked)
Janux Therapeutics’ first-in-human Phase 1, open-label, multicenter trial evaluates JANX014, a prostate-specific membrane antigen (PSMA)–directed CD3 T cell engager designed with “double-masking” so it is…
NCT07545811 First-in-human - New trial Spotlight
Bladder and urothelial cancer
Phase 2 enfortumab vedotin Nectin-4 ADC + pembrolizumab PD-1 inhibitor for bladder preservation.
This open-label, single-arm Phase 2 EV-209 study tests whether continuing enfortumab vedotin plus pembrolizumab can enable durable response and bladder-intact survival (including bladder intact at 2 years) in…
NCT07475806 Exploratory - New trial Spotlight
Colorectal cancer
Phase 3 precemtabart tocentecan (CEACAM5 ADC delivering TOP1 inhibitor exatecan) in previously treated mCRC
This randomized, open-label, 3-arm Phase 3 study (PROCEADE-CRC-03) tests whether precemtabart tocentecan (Precem‑TcT; also known as M9140)—a CEACAM5-targeted antibody–drug conjugate that delivers the topoisomerase 1…
NCT07549412 Registrational - New trial Spotlight
Multiple myeloma
Phase 1 KLN-1010 anti-BCMA CAR gene therapy (in vivo CAR‑T generation)
This first-in-human, open-label, sequential-assignment Phase 1 trial tests KLN-1010, a one-time IV *in vivo* gene therapy intended to generate anti-BCMA CAR‑T cells inside the patient (rather than collecting and…
NCT07075185 First-in-human - New trial Spotlight
Neuroendocrine and adrenal tumors
Phase 3 obrixtamig DLL3×CD3 bispecific T‑cell engager plus platinum/etoposide in DLL3+ epNEC
Boehringer Ingelheim’s multicenter, open-label, randomized Phase 3 trial (NCT07544654) tests whether adding obrixtamig—an IgG-like DLL3×CD3 bispecific antibody that redirects T cells to kill DLL3-expressing tumor…
NCT07544654 Registrational - New trial Spotlight
Stomach and esophageal cancer
Phase 2/3 PF-08634404 PD-1×VEGF bispecific antibody + chemo in 1L PD-L1+ HER2− GE cancers
Pfizer’s Phase 2/3, multicenter, interventional study tests PF-08634404—an investigational bispecific antibody that targets PD-1 (immune checkpoint) and VEGF (angiogenesis signaling)—given with standard first-line…
NCT07392892 Exploratory - New trial Spotlight
Acute myeloid leukemia and MDS
Phase 3 bleximenib (JNJ-75276617) menin–KMT2A interaction inhibitor added to intensive AML chemo
This randomized, double-blind, placebo-controlled Phase 3 trial tests whether adding bleximenib (JNJ-75276617)—an oral small-molecule inhibitor of the menin–KMT2A protein interaction—improves outcomes when layered…
NCT07223814 Registrational - Trial result Spotlight
Melanoma
DC-ATA personal dendritic cell vaccine + PD-1/LAG-3 blockade produced responses in all 6 response-evaluable patients with metastatic melanoma.
Personal DC-ATA is an autologous dendritic-cell vaccine loaded ex vivo with lysate from a short-term autologous tumor cell line (autologous tumor antigens), given here concurrently with standard immune checkpoint…
NCT03743298 - Trial result Spotlight
Melanoma
mRNA-4359 (PD-L1/IDO1 mRNA immunotherapy) + pembrolizumab drives 83% ORR in 1L metastatic melanoma (Phase 1/2)
mRNA-4359 is an intramuscular mRNA cancer antigen therapy encoding PD-L1 and IDO1 epitopes, designed to induce antigen-specific T cells against tumor and immunosuppressive cells, and was combined with pembrolizumab…
NCT05533697 - Trial result Spotlight
Multiple myeloma
Cilta-cel (BCMA CAR-T) drives 71% 30‑mo PFS in standard‑risk lenalidomide‑refractory RRMM (CARTITUDE‑4)
Ciltacabtagene autoleucel (cilta-cel) is an autologous anti‑BCMA CAR‑T therapy evaluated in the randomized Phase 3 CARTITUDE‑4 trial (NCT04181827) in lenalidomide‑refractory relapsed/refractory multiple myeloma after…
NCT04181827 - Trial result Spotlight
Multiple myeloma
Cevostamab (FcRH5×CD3 bispecific) + pom-dex drives ~86–88% ORR and high MRD-negativity in BCMA-naïve RRMM
Cevostamab is an FcRH5×CD3 T-cell–engaging bispecific antibody; here it was combined with pomalidomide (IMiD) plus dexamethasone to augment T-cell activity in the Phase Ib CAMMA 1 Arm B randomized dose-expansion…
NCT04910568 - Trial result Spotlight
Liver and bile duct cancer
Muzastotug (ADG126) masked anti-CTLA-4 + atezolizumab/bevacizumab lifts ORR to 50% in 1L uHCC (tiny n)
Muzastotug (ADG126) is a protease-activated, Treg-depleting anti-CTLA-4 IgG1 designed for tumor-local activation (reported ~10× higher ADCC than ipilimumab) and was added to atezolizumab (PD-L1) + bevacizumab (VEGF)…
NCT04524871 - Trial result Spotlight
Non-small cell lung cancer
Zongertinib (HER2-selective irreversible TKI) hits 76% ORR and 14.4-mo PFS as 1L HER2-mutant NSCLC option
Zongertinib is an oral, irreversible HER2 (ERBB2) tyrosine kinase inhibitor designed to spare wild-type EGFR, evaluated in the Phase 1a/1b Beamion LUNG-1 multicohort trial (NCT04886804) at 120mg QD in previously…
NCT04886804 - Trial result Spotlight
Non-small cell lung cancer
Risvutatug rezetecan (B7-H3 TOP1i ADC) + adebrelimab (PD-L1) posts 47% cORR and 11.2-mo mPFS in 2L+ nsq-NSCLC
Risvutatug rezetecan (Ris-Rez; HS-20093/GSK5764227) is a B7-H3–targeted antibody-drug conjugate delivering a topoisomerase-1 inhibitor payload, combined here with adebrelimab, an anti–PD-L1 monoclonal antibody, in…
NCT06332170 - Trial result Spotlight
Ovarian cancer
ZW191 (FRα-targeted ADC) posts 52% unconfirmed ORR in platinum-resistant ovarian/endometrial cancers (Phase 1)
ZW191 is a folate receptor α (FRα)-targeting antibody–drug conjugate (ADC) evaluated in the ongoing first-in-human ZWI-ZW191-101 Phase 1/2 study (NCT06555744); this Part 1 dose-escalation readout (data cut: Dec 1,…
NCT06555744 - Trial result Spotlight
Ovarian cancer
Relacorilant (glucocorticoid receptor antagonist) + nab-paclitaxel cuts death risk 35% in platinum‑resistant ovarian cancer
Relacorilant is an oral, selective glucocorticoid receptor (GR) antagonist intended to reverse GR-driven chemotherapy resistance; in the open-label Phase 3 ROSELLA trial (GOG-3073/ENGOT-ov72; NCT05257408),…
NCT05257408 - Trial result Spotlight
Small cell lung cancer
ZL-1310 (DLL3-targeted topo I ADC) drives 58% intracranial responses in ES-SCLC brain mets
ZL-1310 is a DLL3-targeted antibody–drug conjugate using the TMALIN® platform (protease-cleavable linker delivering a topoisomerase I inhibitor payload) evaluated in a multi-country Phase 1 dose-escalation trial in…
NCT06179069 - Trial result Spotlight
Colorectal cancer
ADG126 (masked anti-CTLA-4) + pembrolizumab + fruquintinib drives 25–50% PRs in 4L MSS CRC (early Ph1b)
ADG126 (muzastotug) is a protease-activated “masked” anti-CTLA-4 IgG1 designed for tumor-selective CTLA-4 engagement, here combined with pembrolizumab (PD-1) and fruquintinib (VEGFR1/2/3 TKI) in a Phase 1b 4th-line…
NCT05405595 - Trial result Spotlight
Multiple solid tumors
Zedoresertib (WEE1) + Lunresertib (PKMYT1) Shows Early Tumor Shrinkage in CCNE1/FBXW7-Altered Solid Tumors (notably ovarian)
Zedoresertib is an oral, selective WEE1 inhibitor and lunresertib is an oral, selective PKMYT1 inhibitor; dual checkpoint abrogation is designed to force premature mitotic entry under replication stress, driving…
NCT04855656 - Trial result Spotlight
Multiple solid tumors
Elisrasib (D3S-001) GDP-bound KRAS G12C inhibitor drives 62% ORR in mCRC with cetuximab—and 68% ORR as monotherapy in PDAC
Elisrasib (D3S-001) is an oral, next-generation KRAS G12C inhibitor engineered to bind the GDP-bound state and resist growth factor–driven nucleotide exchange; in KRAS G12C–mutant mCRC it was also combined with…
NCT05410145 - New trial Spotlight
Pancreatic cancer
Phase 3 INCB161734 KRAS G12D–selective inhibitor plus chemo in metastatic PDAC
In this randomized, double-blind Phase 3 DAWN-303 trial from Incyte, patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) whose tumors harbor a KRAS G12D mutation are assigned to…
NCT07522073 Registrational - New trial Spotlight
Non-small cell lung cancer
Phase 1/2 ivonescimab PD-1×VEGF-A bispecific with Dato-DXd TROP2 ADC or osimertinib EGFR TKI
MSK is running a non-randomized, open-label Phase 1/2 trial in metastatic EGFR-activating–mutant NSCLC after prior EGFR TKI therapy, testing a fixed dose of ivonescimab (a PD-1 and VEGF-A–targeted bispecific…
NCT07535437 Exploratory - New trial Spotlight
Prostate cancer
Phase 1/2 AZD8359 STEAP2-targeted CD8-guided T cell–engaging antibody in metastatic prostate cancer
This first-in-human, modular, open-label Phase 1/2 study (CRIUS-1) from AstraZeneca evaluates AZD8359, a T cell–engaging antibody designed to direct CD8 T cells toward STEAP2-expressing prostate cancer cells (STEAP2…
NCT07529717 First-in-human - New trial Spotlight
Colorectal cancer
Phase 1 BAY 3771249 KRAS G12D-selective inhibitor ± EGFR antibody cetuximab in mCRC
Bayer (with partner Kumquat Biosciences) is running an open-label Phase 1 master protocol testing BAY 3771249 (also referenced as KQB548), an oral small-molecule KRAS G12D-selective inhibitor, given alone or combined…
NCT07535112 Exploratory - New trial Spotlight
Myeloproliferative neoplasms
Phase 1 PRT12396 mutant-selective JAK2V617F inhibitor (allosteric JH2 “pseudokinase” inhibitor) in PV/MF
Prelude Therapeutics is running a first-in-human, open-label, multi-center Phase 1 dose-escalation/expansion study testing PRT12396, an oral, twice-daily small molecule designed to selectively inhibit the JAK2 V617F…
NCT07469891 First-in-human
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.